title: Modified Welsh regimen: a promising therapy for actinomycetoma.
abstract: BACKGROUND
  Mycetoma has a worldwide geographical distribution which is extremely uneven; however, it is a common disease in India and responsible for causing significant morbidity. Treatment of this condition is often a challenge for the treating dermatologist. The authors report a promising therapy for patients of actinomycotic mycetoma.
  
  
  METHODS
  This assessment series included 18 patients with a confirmed diagnosis of actinomycetoma, and who had shown a poor response to previous treatments. Patient received a combination therapy of the Welsh regimen (amikacin along with cotrimoxazole) to which rifampicin was added as a third drug. Clinical evaluation included radiology and laboratory investigations.
  
  
  RESULTS
  Sixteen patients out of 18 completed the combination therapy, which lead to remission. Two patients were lost to follow-up. Of the 16 patients in remission, no recurrence was observed during a follow-up period of up to 18 months.
authors.affiliation: Department of Dermatology, B.J. Medical College, Pune, Maharashtra State, India. drdkdamle@rediffmail.com
authors.forename: D K
authors.initials: DK
authors.lastname: Damle
authors.forename: P M
authors.initials: PM
authors.lastname: Mahajan
authors.forename: S N
authors.initials: SN
authors.lastname: Pradhan
authors.forename: V A
authors.initials: VA
authors.lastname: Belgaumkar
authors.forename: A P
authors.initials: AP
authors.lastname: Gosavi
authors.forename: S N
authors.initials: SN
authors.lastname: Tolat
authors.forename: N R
authors.initials: NR
authors.lastname: Gokhale
authors.forename: C B
authors.initials: CB
authors.lastname: Mhaske
mesh_terms: D000328:Adult; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008271:Mycetoma / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D012074:Remission Induction / Q000379:methods; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000583:Amikacin; D012293:Rifampin